[1]
Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (London, England). 2016 Nov:30(11):1526. doi: 10.1038/eye.2016.202. Epub 2016 Sep 9
[PubMed PMID: 27612184]
[2]
Chen Y, Han F. Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Therapeutics and clinical risk management. 2012:8():343-51. doi: 10.2147/TCRM.S32801. Epub 2012 Jul 11
[PubMed PMID: 22911433]
[3]
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Feb 10:23(5):1011-27
[PubMed PMID: 15585754]
[4]
Krispel C, Rodrigues M, Xin X, Sodhi A. Ranibizumab in diabetic macular edema. World journal of diabetes. 2013 Dec 15:4(6):310-8. doi: 10.4239/wjd.v4.i6.310. Epub
[PubMed PMID: 24379922]
[5]
Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2009:23(5):289-304. doi: 10.2165/11317600-000000000-00000. Epub
[PubMed PMID: 19754219]
[6]
Lin RC, Rosenfeld PJ. Antiangiogenic therapy in neovascular age-related macular degeneration. International ophthalmology clinics. 2007 Winter:47(1):117-37
[PubMed PMID: 17237677]
[7]
Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature medicine. 1995 Oct:1(10):1024-8
[PubMed PMID: 7489357]
[8]
Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. The American journal of pathology. 2012 Aug:181(2):376-9. doi: 10.1016/j.ajpath.2012.06.006. Epub 2012 Jun 29
[PubMed PMID: 22749677]
[9]
CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England journal of medicine. 2011 May 19:364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28
[PubMed PMID: 21526923]
[10]
Joachim SC, Renner M, Reinhard J, Theiss C, May C, Lohmann S, Reinehr S, Stute G, Faissner A, Marcus K, Dick HB. Protective effects on the retina after ranibizumab treatment in an ischemia model. PloS one. 2017:12(8):e0182407. doi: 10.1371/journal.pone.0182407. Epub 2017 Aug 11
[PubMed PMID: 28800629]
[11]
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr:119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11
[PubMed PMID: 22330964]
Level 1 (high-level) evidence
[12]
Evoy KE, Abel SR. Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema. The Annals of pharmacotherapy. 2013 Jun:47(6):811-8. doi: 10.1345/aph.1S013. Epub 2013 May 8
[PubMed PMID: 23656749]
[13]
van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM, Grutters JPC. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PloS one. 2018:13(5):e0197670. doi: 10.1371/journal.pone.0197670. Epub 2018 May 17
[PubMed PMID: 29772018]
Level 3 (low-level) evidence
[14]
Mohamad NA, Ramachandran V, Ismail P, Mohd Isa H, Chan YM, Ngah NF, Md Bakri N, Ching SM, Hoo FK, Wan Sulaiman WA. Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia. International journal of ophthalmology. 2017:10(12):1889-1897. doi: 10.18240/ijo.2017.12.16. Epub 2017 Dec 18
[PubMed PMID: 29259909]
[16]
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012 Jun:15(2):171-85. doi: 10.1007/s10456-011-9249-6. Epub
[PubMed PMID: 22302382]
[17]
Dugel PU, Singh N, Francom S, Cantrell RA, Grzeschik SM, Fung AE. The Systemic Safety of Ranibizumab in Patients 85 Years and Older with Neovascular Age-Related Macular Degeneration. Ophthalmology. Retina. 2018 Jul:2(7):667-675. doi: 10.1016/j.oret.2018.01.010. Epub 2018 Feb 27
[PubMed PMID: 31047375]
[18]
Stewart MW. A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and therapy. 2017 Jun:6(1):33-47. doi: 10.1007/s40123-017-0083-9. Epub 2017 Mar 21
[PubMed PMID: 28324452]
[19]
Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA ophthalmology. 2015 May:133(5):589-97. doi: 10.1001/jamaophthalmol.2015.186. Epub
[PubMed PMID: 25719991]
[20]
Wang W, Zhang X. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PloS one. 2014:9(10):e109744. doi: 10.1371/journal.pone.0109744. Epub 2014 Oct 16
[PubMed PMID: 25330364]
Level 1 (high-level) evidence
[21]
Kampougeris G, Spyropoulos D, Mitropoulou A. Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and Correlations. Journal of current glaucoma practice. 2013 Jan-Apr:7(1):19-24. doi: 10.5005/jp-journals-10008-1132. Epub 2013 Jan 15
[PubMed PMID: 26997776]
[22]
Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (London, England). 2013 Jul:27(7):787-94. doi: 10.1038/eye.2013.107. Epub 2013 May 31
[PubMed PMID: 23722722]
[23]
Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina (Philadelphia, Pa.). 2008 Nov-Dec:28(10):1395-9. doi: 10.1097/IAE.0b013e3181884fd2. Epub
[PubMed PMID: 18827737]
[24]
Karagiannis DA, Mitropoulos P, Ladas ID. Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2009:223(4):279-82. doi: 10.1159/000213644. Epub 2009 Apr 22
[PubMed PMID: 19390227]
[25]
Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina (Philadelphia, Pa.). 2009 Mar:29(3):319-24. doi: 10.1097/IAE.0b013e318198148e. Epub
[PubMed PMID: 19287288]
[26]
Lim LS, Cheung CMG, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? American journal of ophthalmology. 2011 Sep:152(3):329-331. doi: 10.1016/j.ajo.2011.05.040. Epub
[PubMed PMID: 21855670]
[27]
Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, Souied E, Figueroa MS, LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. The British journal of ophthalmology. 2013 Sep:97(9):1161-7. doi: 10.1136/bjophthalmol-2013-303232. Epub 2013 Jul 13
[PubMed PMID: 23850682]
Level 2 (mid-level) evidence
[28]
Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Investigative ophthalmology & visual science. 2013 Mar 5:54(3):1616-24. doi: 10.1167/iovs.12-10260. Epub 2013 Mar 5
[PubMed PMID: 23361508]
[29]
Manousaridis K, Talks J. Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? The British journal of ophthalmology. 2012 Feb:96(2):179-84. doi: 10.1136/bjophthalmol-2011-301087. Epub
[PubMed PMID: 22250209]
[30]
Merz PR, Röckel N, Ballikaya S, Auffarth GU, Schmack I. Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells. BMC ophthalmology. 2018 Dec 11:18(1):316. doi: 10.1186/s12886-018-0978-9. Epub 2018 Dec 11
[PubMed PMID: 30537942]